Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Guardant Health (GH)
Consensus Price Target: $130.52 (15.1% implied return)
Pioneering the field of "liquid biopsy" with technology that can identify cancer-specific genetic mutations from a simple blood draw, Guardant Health (NASDAQ: GH) develops blood tests that detect and monitor cancer by analyzing tumor DNA in the bloodstream, helping doctors make treatment decisions without invasive biopsies.
Why Does GH Fall Short?
- Modest revenue base of $1.08 billion means it has less operating leverage but can also grow faster if it executes the right sales strategy
- Cash burn makes us question whether it can achieve sustainable long-term growth
- Negative earnings profile makes it challenging to secure favorable financing terms from lenders
Guardant Health is trading at $113.44 per share, or 9.3x forward price-to-sales. Read our free research report to see why you should think twice about including GH in your portfolio.
Albertsons (ACI)
Consensus Price Target: $20.94 (24.2% implied return)
With over 20 well-known grocery banners spanning 34 states, Albertsons (NYSE: ACI) operates food and drug retail stores across the US, offering groceries, pharmacy services, and own-brand products under banners like Safeway, Jewel-Osco, and Vons.
Why Should You Sell ACI?
- Lack of new stores puts a ceiling on its growth and reflects a focus on optimizing sales at existing locations
- Widely-available products (and therefore stiff competition) result in an inferior gross margin of 27.5% that must be offset through higher volumes
- Responsiveness to unforeseen market trends is restricted due to its substandard operating margin profitability
Albertsons’s stock price of $16.86 implies a valuation ratio of 7.7x forward P/E. If you’re considering ACI for your portfolio, see our FREE research report to learn more.
Phibro Animal Health (PAHC)
Consensus Price Target: $45.60 (31.2% implied return)
With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ: PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.
Why Is PAHC Not Exciting?
- Subscale operations are evident in its revenue base of $1.5 billion, meaning it has fewer distribution channels than its larger rivals
- Estimated sales growth of 2% for the next 12 months implies demand will slow from its two-year trend
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
At $34.76 per share, Phibro Animal Health trades at 10.5x forward P/E. Check out our free in-depth research report to learn more about why PAHC doesn’t pass our bar.
Stocks We Like More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
